Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rescigno

Showing results (551-560 of 1,117) with videos related to

Pageof 112
Sort By:
Current Issues in Molecular Biology|July 23, 2025
Microbiota Modulation of Radiosensitiveness and Toxicity in Gastrointestinal Cancers: What Radiation Oncologists Need to Know-A Review on Behalf of the Italian Association of Radiobiology (AIRB)Marco Lorenzo Bonù, Andrea Georgopulos, Marco Ramera, et al.
Minerva Urology and Nephrology|October 23, 2025
The added value of PSMA PET to nomograms in identifying optimal candidates for extended pelvic lymph node dissection in intermediate-risk prostate cancer patientsMatteo Bauckneht, Enrico Checcucci, Francesco Lanfranchi, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancerAndreas Schneeweiss, Laura L Michel, Volker Möbus, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
European Urology|July 27, 2019
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Beshara Sheehan, Ruth Riisnaes, et al.
Clinical Genitourinary Cancer|June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden HospitalDiletta Bianchini, David Lorente, Pasquale Rescigno, et al.
Clinical Genitourinary Cancer|November 6, 2023
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Journal of the National Cancer Institute|December 28, 2021
Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian CancerKonstantin Weber-Lassalle, Corinna Ernst, Alexander Reuss, et al.
The Oncologist|August 3, 2022
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO NetworkPasquale Rescigno, Marco Maruzzo, Sara Elena Rebuzzi, et al.
Pageof 112

Showing results (551-560 of 1,117) with videos related to

Sort By:
Pageof 112
Current Issues in Molecular Biology|July 23, 2025
Microbiota Modulation of Radiosensitiveness and Toxicity in Gastrointestinal Cancers: What Radiation Oncologists Need to Know-A Review on Behalf of the Italian Association of Radiobiology (AIRB)Marco Lorenzo Bonù, Andrea Georgopulos, Marco Ramera, et al.
Minerva Urology and Nephrology|October 23, 2025
The added value of PSMA PET to nomograms in identifying optimal candidates for extended pelvic lymph node dissection in intermediate-risk prostate cancer patientsMatteo Bauckneht, Enrico Checcucci, Francesco Lanfranchi, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancerAndreas Schneeweiss, Laura L Michel, Volker Möbus, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
European Urology|July 27, 2019
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Beshara Sheehan, Ruth Riisnaes, et al.
Clinical Genitourinary Cancer|June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden HospitalDiletta Bianchini, David Lorente, Pasquale Rescigno, et al.
Clinical Genitourinary Cancer|November 6, 2023
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Journal of the National Cancer Institute|December 28, 2021
Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian CancerKonstantin Weber-Lassalle, Corinna Ernst, Alexander Reuss, et al.
The Oncologist|August 3, 2022
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO NetworkPasquale Rescigno, Marco Maruzzo, Sara Elena Rebuzzi, et al.
Pageof 112